Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nineteen research firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $745.95.
Several analysts have recently weighed in on LLY shares. Truist Financial reissued a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th.
Check Out Our Latest Analysis on LLY
Hedge Funds Weigh In On Eli Lilly and Company
Eli Lilly and Company Price Performance
Shares of NYSE:LLY opened at $781.56 on Friday. Eli Lilly and Company has a 1-year low of $392.26 and a 1-year high of $800.78. The firm has a market capitalization of $742.61 billion, a PE ratio of 134.75, a PEG ratio of 1.60 and a beta of 0.34. The business’s 50 day moving average is $761.41 and its 200-day moving average is $669.21. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, missing the consensus estimate of $2.61 by ($0.03). Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the business posted $1.62 EPS. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- What is a Low P/E Ratio and What Does it Tell Investors?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Hilton Demonstrates Asset Light is Right for Investors
- Technology Stocks Explained: Here’s What to Know About Tech
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.